Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
about
An update on the diagnosis and treatment of Parkinson diseasePioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.DRUM-PD: The use of a drum circle to improve the symptoms and signs of Parkinson's disease (PD)Deep brain stimulation of caudal zona incerta and subthalamic nucleus in patients with Parkinson's disease: effects on voice intensityNeural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis.Current clinical practice for Parkinson's disease among Chinese physicians, general neurologists and movement disorders specialists: a national survey.Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degenerationQuality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.Pleurotus giganteus (Berk.) Karunarathna & K.D. Hyde: Nutritional value and in vitro neurite outgrowth activity in rat pheochromocytoma cells.Seniors with Parkinson's disease: initial medical treatment.Two-year exercise program improves physical function in Parkinson's disease: the PRET-PD randomized clinical trial.Trends in inpatient antiparkinson drug use in the USA, 2001-2012.Can the disease course in Parkinson's disease be slowed?Promoting exercise in Parkinson's disease through community-based participatory research.Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.The quantity and quality of complementary and alternative medicine clinical practice guidelines on herbal medicines, acupuncture and spinal manipulation: systematic review and assessment using AGREE IIThe Antiparkinsonian and Antidyskinetic Mechanisms of Mucuna pruriens in the MPTP-Treated Nonhuman Primate.Pharmacotherapy for Parkinson's disease.Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts.Treatment options for non-motor symptoms in late-stage Parkinson's disease.Protection against Parkinson's disease progression: clinical experience.Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life StudyTargets for neuroprotection in Parkinson's diseaseTai Ji Quan Exercise for People with Parkinson's Disease and Other Neurodegenerative Movement DisordersMicronutrients and Risk of Parkinson's Disease: A Systematic Review.Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition.Olfaction as a biomarker in Parkinson's disease.Parkinson's disease--the continuing search for biomarkers.Physical, occupational, speech and swallowing therapies and physical exercise in Parkinson's disease.Balance and falls in Parkinson's disease: a meta-analysis of the effect of exercise and motor training.The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.Cheaper, simpler, and better: tips for treating seniors with Parkinson disease.Exercise and motor training in people with Parkinson's disease: a systematic review of participant characteristics, intervention delivery, retention rates, adherence, and adverse events in clinical trials.Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease.The timing of deep brain stimulation for Parkinson disease in the UK from 1997 to 2012.Opicapone for the treatment of Parkinson's disease.The impact of Tai Chi and Qigong mind-body exercises on motor and non-motor function and quality of life in Parkinson's disease: A systematic review and meta-analysis.Exploring the potential of natural and synthetic neuroprotective steroids against neurodegenerative disorders: A literature review.
P2860
Q30243899-7CF60FD3-DB3C-427D-A113-ED281F12C728Q30357397-6A6DDC47-53F9-4C4A-91B4-DE544FC83E56Q30389730-6B1C3D6D-1A68-4AAA-9899-4252417A725BQ30473590-00C6850F-25ED-4988-838D-6E8E7AEADDD4Q30477266-48046574-8479-43AF-9678-F1B6C8DF4239Q31108322-5ADD9995-480A-4C4A-87D2-CE1A978892CEQ33828847-50F3A6FF-0A27-44FA-8129-0AC92F5FC481Q34152355-D1D67776-D767-42E6-A275-44A8BEB6BAABQ34343765-2F1A2A87-5272-4F9E-996E-A05223F55542Q34508143-E91220B5-0F67-4021-BF94-92791E2822CCQ34772565-36A09BF9-7AB4-4F7E-8F71-0B04B40E5CC3Q35847512-CF7F727A-F1A3-4DD1-ADE2-11846F43736FQ35865171-4965B2C9-9070-479E-9725-16D9244064F9Q35915858-BE8656A5-8F90-4D84-BB4E-479361D6B877Q36164724-2D631803-A70B-4DD5-AE81-D1351501A065Q36177578-7536A6B4-4A89-4AEA-9FE4-9CD3702900EAQ36241835-E25E0173-911C-42EC-ADE2-5EEE39F1F5AAQ37016031-E0320A5F-C295-4BCA-A1C4-B2EAE63775CCQ37016034-491B20BC-86EA-4FAC-B56E-947FCDA5727BQ37036351-83D29662-E97D-4754-86E5-3238B8FDB4C8Q37098986-4C33CEF4-4168-4601-902A-B08D591E9255Q37131239-3DA2AD43-DD7E-4291-8066-E9EAA39B1C4EQ37265848-89B57124-1CD9-4733-8995-E7D89AEFBF75Q37302453-DC53A4E5-FFAC-48EA-B04A-FC1DEECB6A39Q37307292-49565D2C-23A1-4191-BF8A-2EFDADF88EE4Q37429643-0E8B20F2-CA12-461C-90C4-4178756A3586Q37724555-EE02C39B-3EF6-4B14-8AB1-61D91B5E2B6EQ37779428-EDB2F6BB-988A-4746-AD9D-AA7068B80E64Q37800097-669AA33C-26F1-4CA7-8CE3-88A6F70E1074Q37834648-95FAA907-AADC-4F84-87EC-0925C9B94A34Q37861015-F98A5F6C-8954-4E44-B91A-70660C6546ACQ37889787-EB49FEC2-7111-4640-AF04-28C9177A9D89Q37948713-49B2E976-76D8-45FD-A2AE-A7A7FDAB8F9FQ37963796-3E42733F-193A-4923-80BD-8EFEB9A9456CQ37970687-FA070661-7E0F-431D-9F51-C19FA3C3A4A7Q38250185-560A5243-8F42-429A-AD56-6C2E01D80417Q38587027-6725A7EE-9AB1-4E48-93E8-FF11A5047541Q38943872-EBD9C0B2-74A2-467A-8E98-D5BE06885060Q39365181-F06A2929-2B58-48B0-BB00-9B71AEBF9EECQ39428788-10FF6725-C497-436A-BA71-96F5B18AA3D6
P2860
Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Practice Parameter: Neuroprote ...... American Academy of Neurology
@ast
Practice Parameter: Neuroprote ...... American Academy of Neurology
@en
Practice Parameter: Neuroprote ...... American Academy of Neurology
@en-gb
Practice Parameter: Neuroprote ...... American Academy of Neurology
@nl
type
label
Practice Parameter: Neuroprote ...... American Academy of Neurology
@ast
Practice Parameter: Neuroprote ...... American Academy of Neurology
@en
Practice Parameter: Neuroprote ...... American Academy of Neurology
@en-gb
Practice Parameter: Neuroprote ...... American Academy of Neurology
@nl
altLabel
Practice Parameter: neuroprote ...... American Academy of Neurology
@en
prefLabel
Practice Parameter: Neuroprote ...... American Academy of Neurology
@ast
Practice Parameter: Neuroprote ...... American Academy of Neurology
@en
Practice Parameter: Neuroprote ...... American Academy of Neurology
@en-gb
Practice Parameter: Neuroprote ...... American Academy of Neurology
@nl
P2093
P3181
P1433
P1476
Practice Parameter: Neuroprote ...... American Academy of Neurology
@en
P2093
G. Gronseth
J. Perlmutter
O. Suchowersky
T. Zesiewicz
W. J. Weiner
P304
P3181
P356
10.1212/01.WNL.0000206363.57955.1B
P407
P577
2006-04-02T00:00:00Z